+44 (0)1482 631606

Matoke Holdings is a British biotechnology company which has developed a novel Reactive Oxygen® technology platform. This patent protected technology delivers outstanding antimicrobial activity against all the WHO crisis bacteria, including multidrug resistant strains. Through the work of leading University researchers the technology has also been shown to disrupt and destroy biofilm and may also act as an immunomodulatory stimulus to further improve wound healing. Reactive Oxygen® “the next major breakthrough in topical and deep surgical wound healing and infection control.” Matoke is developing a portfolio of products based on this Reactive Oxygen® technology, which it believes will be transformative in the treatment of acute and chronic wounds and, by virtue of its mode of action, is unlikely to encourage the development of resistance. It is therefore likely to play an important role in sparing the use of conventional antibiotics. A substantial body of clinical evidence of the efficacy of the technology exists in the literature and new publications are in development.


Click the images below to go to the product pages

Surgihoney RO

Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Consent to display content from - Youtube
Consent to display content from - Vimeo
Google Maps
Consent to display content from - Google
Consent to display content from - Spotify
Sound Cloud
Consent to display content from - Sound